Pharma stock to buy: Anil Singhvi picks this pharma stock for up to 68% upside; check out target

At 11.57 AM, the Sensex was at 81,923.94, up 144 points, while the Nifty was up 28 points to 25,080.05.

The rupee rose 9 paise to 83.88 vs the US dollar in early trade on Thursday helped by the American currency's weakness in the international market and a strong trend in local markets.

Meanwhile, Zee Business managing editor and market wizard Anil Singhvi has picked Aarti Pharmalabs as a winning stock for the long-term.

Singhvi suggests buying the stock for 1-2 years.

The target is Rs 800, Rs 950, and Rs 1100. 

He suggests doing an SIP on every 10 per cent fall.

The stock closed at Rs 653.8 each on Wednesday, August 29. This means, it has a potential upside of up to 70 per cent from its last closing price.

Currently, the stock is trading almost 8 per cent up at Rs 704.9 apiece on BSE at 11.49 AM IST.

Aarti Pharmalabs Limited (APL) is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India.

Anil Singhvi says, the guidance from the management is strong. The company's CDMO/CMO is aiming for 25-30 per cent growth in business income in the financial year 2025. Besides, work on 25-30 capacity expansion is also going on. That is why they are continuously doing Capex, so that their future growth also remains intact.

The company's focus is on value-added products and high-margin products. This is a stock of the pharma sector. This is a less-known stock as of now. This stock can do wonders in the future. You can make purchases relying on this. SIP has to be done for every 10 per cent fall.